secwatch.observer — SEC 8-K summary
======================================

Issuer:     Liminatus Pharma, Inc. (LIMN)
CIK:        0001971387
Form:       8-K
Filed at:   2026-05-20T21:00:24+00:00
Accession:  0001104659-26-064585
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Liminatus Pharma to acquire InnocsAI in stock merger valued at ~$320M
---------------------------------------------------------------------

- 1.6B shares at $0.20/share ($320M aggregate) plus contingent value rights of 20% of future net proceeds from asset sale.
- Assets include CAR-T pipeline: IBC101 (Phase 1/2a in Korea for DLBCL) and preclinical INC101 for solid tumors.
- CEO Chris Kim also controls Valetudo Therapeutics LLC, a member of InnocsAI, making the transaction a related-party deal.
- Closing targeted by Dec 31, 2026, subject to stockholder approvals and other customary conditions.
- Liminatus to file a registration statement/proxy statement for the stockholder vote.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1971387/000110465926064585/0001104659-26-064585-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1971387/000110465926064585/tm2615228d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-064585

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer